# ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer

> **NCT06902272** · PHASE2 · RECRUITING · sponsor: **University of Miami** · enrollment: 30 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay
- **DRUG:** Pembrolizumab
- **DRUG:** Platinum Doublet Chemotherapy

## Key facts

- **NCT ID:** NCT06902272
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-11
- **Primary completion:** 2028-06-11
- **Final completion:** 2029-06-11
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06902272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06902272, "ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06902272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*